Clinaptis Releases Research on Viking Therapeutics Drug Portfolio

AMRITSAR, India - Aug. 4, 2026 - PRLog -- AMRITSAR, India  August 5, 2026 — Clinaptis Research today announced the publication of a new independent research report examining Viking Therapeutics and the evolving investment case for its lead obesity candidate, VK2735.

The report develops a reverse-solve valuation framework that separates the value of VK2735's subcutaneous franchise from the unresolved commercial opportunity represented by its oral formulation. Rather than asking whether the company is simply undervalued or overvalued, the analysis evaluates which variables the market has already priced and which remain dependent on future clinical and development decisions.

Key findings

• Base-case analysis suggests the subcutaneous VK2735 program alone supports approximately 66% of Viking's current ex-cash enterprise value.
• Approximately 608,000 peak treated obesity patients would be required for the subcutaneous franchise alone to fully justify today's enterprise value under the model assumptions.

VKTX 2735 Investment Case

• The report argues that the market may have attributed the oral Phase 2 discontinuation rate primarily to the molecule itself, while the available evidence also supports a development strategy and dose-escalation interpretation that remains unresolved pending Phase 3.
• The upcoming oral Phase 3 dose selection and protocol disclosure is identified as the most important remaining catalyst for valuation, ahead of future efficacy readouts.

The report combines clinical trial evidence, commercial market analysis, competitive benchmarking, payer dynamics and valuation modelling to examine the long-term commercial positioning of VK2735 within the rapidly evolving obesity therapeutics landscape. It also develops a catalyst framework mapping future clinical and regulatory milestones directly to valuation variables rather than treating each event independently.

The complete report is available at:
https://bkkaler.substack.com/p/viking-therapeutics-vktx-r...

About Clinaptis Research

Clinaptis Research is an independent biopharmaceutical intelligence platform focused on therapeutic area research, clinical evidence synthesis, market intelligence and advanced data analytics. Current coverage includes obesity and cardiometabolic disease, neuroscience, rare diseases, sleep medicine and metabolic dysfunction-associated steatohepatitis (MASH), with additional therapeutic areas under development.

Media Contact

Bikram K. Singh, MBBS

Principal Analyst

Clinaptis Research

bikram@clinaptisresearch.com

Disclaimer

This announcement summarizes an independent research publication prepared by Clinaptis Research. It is intended solely for informational, educational and market research purposes and does not constitute investment advice, an offer, or a recommendation to buy or sell any security. Readers should review the complete report, including its assumptions, methodology and disclosures, before making investment decisions.